Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,723.42 +77.72 (+0.11%) CMC Crypto 200
1,425.97 -2.60 (-0.18%)
XERS Dec 2024 1.500 call
- Business Wire
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
CHICAGO, May 30, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection
- Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
CHICAGO, May 30, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time.
- GuruFocus.com
Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges
Performance Surpasses Revenue Estimates but Misses on EPS
